NCT01459380 - Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2011

Primary Completion Date

June 8, 2016

Study Completion Date

February 11, 2017

Conditions

Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUndifferentiated Ovarian Carcinoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

DRUG

Veliparib

Given PO

Trial Locations (13)

10065

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

30912

Augusta University Medical Center, Augusta

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

60637

University of Chicago Comprehensive Cancer Center, Chicago

73104

University of Oklahoma Health Sciences Center, Oklahoma City

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

02905

Women and Infants Hospital, Providence